• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Lee Soo Young

    11/15/24 8:34:39 PM ET
    $ACAB
    Blank Checks
    Finance
    Get the next $ACAB alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Lee Soo Young

    (Last) (First) (Middle)
    C/O ABPRO HOLDINGS, INC.
    68 CUMMINGS PARK DRIVE

    (Street)
    WOBURN MA 01801

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    11/13/2024
    3. Issuer Name and Ticker or Trading Symbol
    Abpro Holdings, Inc. [ ABP ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact 11/15/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ACAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACAB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ACAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Atlantic Coastal Acquisition Corp. II Receives Notification of Deficiency from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

      NEW YORK, June 13, 2024 /PRNewswire/ -- Atlantic Coastal Acquisition Corp. II (NASDAQ:ACAB) (the "Company"), a special purpose acquisition company, announced that it had previously received written notification (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on June 3, 2024 that, because the Company had not yet filed its Quarterly Report on Form 10-Q for the three month period ended March 31, 2024 (the "10-Q") with the Securities and Exchange Commission (the "SEC"), the Company was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1). The Notice has no immediate effect on the listing of the Company

      6/13/24 4:15:00 PM ET
      $ACAB
      Blank Checks
      Finance
    • Abpro Announces Filing of Registration Statement on Form S-4 in Connection with Business Combination Agreement with Atlantic Coastal Acquisition Corp. II

      WOBURN, Mass. and NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Abpro Corporation ("Abpro"), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies, and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACAB), a special purpose acquisition company ("Atlantic Coastal"), today announced the filing of a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") on January 19, 2024, which includes a preliminary proxy statement and prospectus in connection with its proposed business combination. Upon the closing of the proposed business

      1/22/24 8:00:00 AM ET
      $ACAB
      Blank Checks
      Finance
    • Abpro to Become Publicly Traded via Merger with Atlantic Coastal Acquisition Corp. II

      Abpro is a biotechnology company specializing in the development of next-generation antibody therapies intended to improve the lives of those with life-threatening diseases. The transaction values Abpro at $725 million and will help advance Abpro's drug pipeline to clinical trials. Abpro Corporation ("Abpro"), a biotechnology company with the mission of improving the lives of those facing severe and life-threatening diseases with next-generation antibody therapies, and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACAB), a special purpose acquisition corporation ("Atlantic Costal"), today announced a term sheet to enter into a definitive business combination, which was entered into o

      9/21/23 4:00:00 PM ET
      $ACAB
      Blank Checks
      Finance

    $ACAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Atlantic Coastal Acquisition Corp. II (Amendment)

      SC 13G/A - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

      2/7/24 1:53:24 PM ET
      $ACAB
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Atlantic Coastal Acquisition Corp. II (Amendment)

      SC 13G/A - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

      1/19/24 4:17:41 PM ET
      $ACAB
      Blank Checks
      Finance
    • SEC Form SC 13D filed by Atlantic Coastal Acquisition Corp. II

      SC 13D - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

      4/20/23 6:01:50 AM ET
      $ACAB
      Blank Checks
      Finance

    $ACAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Abpro Bio International, Inc. claimed ownership of 16,507,334 shares (SEC Form 3)

      3 - Abpro Holdings, Inc. (0001893219) (Issuer)

      11/18/24 9:00:34 PM ET
      $ACAB
      Blank Checks
      Finance
    • SEC Form 3 filed by new insider Mcdonald Ian

      3 - Abpro Holdings, Inc. (0001893219) (Issuer)

      11/18/24 8:52:41 PM ET
      $ACAB
      Blank Checks
      Finance
    • Co-CEO & Chairman Suk Jin Wook (Miles) was granted 91,900 shares (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      11/15/24 9:34:52 PM ET
      $ACAB
      Blank Checks
      Finance

    $ACAB
    SEC Filings

    See more
    • SEC Form NT 10-Q filed by Atlantic Coastal Acquisition Corp. II

      NT 10-Q - Abpro Holdings, Inc. (0001893219) (Filer)

      11/15/24 4:05:03 PM ET
      $ACAB
      Blank Checks
      Finance
    • Atlantic Coastal Acquisition Corp. II filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Abpro Holdings, Inc. (0001893219) (Filer)

      11/13/24 5:21:02 PM ET
      $ACAB
      Blank Checks
      Finance
    • SEC Form 25-NSE filed by Atlantic Coastal Acquisition Corp. II

      25-NSE - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

      11/12/24 4:31:03 PM ET
      $ACAB
      Blank Checks
      Finance